Introduction
============

Fever is a complex pathological process that manifests itself as a regulated elevation of body temperature over the normal circadian variations. Although fever may be regarded as a host defense response, it has potentially harmful consequences such as convulsions, dehydration, especially brain damage and seizures usually happen during severe and long-lasting fever in children [@B1]. Therefore, quite a number of people think that fever is a disease rather than a symptom or sign of illness and it is important to keep the body temperature in the state of homeostasis within the narrow range.

As a thermoregulatory manifestation to systemic inflammation, fever has been studied for years. Our understanding of the molecular mechanisms has substantially advanced over the past decade, and major advances have been made since the discovery of the transient receptor potential (TRP) family. They are strong candidates for a role in temperature sensing and regulating as evidenced by gating at different temperature thresholds [@B2]. For example, transient receptor potential vanilloid type 1 (TRPV1) is the sensor for uncomfortably warm (\>43℃) temperatures [@B3], [@B4], whereas TRPM8 and TRPA1 appear to function in our perception of cool temperatures [@B5], [@B6]. There is an abundance of literature reporting that TRP channels may be activated by potential endogenous activators and regulators produced in inflammatory tissues [@B7]. Interestingly, these TRPs can also be activated by compounds from foods or traditional Chinese medicines (TCM). For example, TRPV1 is activated by ingredients of spicy foods such as hot pepper (capsaicin) [@B8] and ginger (gingerols and shogaols) [@B9], [@B10]. TRPM8 is activated by ingredients of peppermint (menthol) [@B11]. And TRPA1 is activated by ingredients of galic (allicin)[@B12] and cinnamon (cinnamaldehyde) [@B13]. Fructus Forsythiae, the fruit of *Forsythia suspense* (Thunb.) Vahl (Oleaceae), is a widely used traditional Chinese medicine (TCM) in the treatment of inflammation, pyrexia or emesis. Forsythoside A (FT-A) is one of the main phenylethanoid glycosides, and the most abundant active ingredients in Fructus Forsythiae, which possesses strong antimicrobial, antiviral and antioxidative activities [@B14], [@B15]. According to the literature and the clinical practice in TCM, Fructus Forsythiae shows obvious efficacy in alleviating fever. However, the antipyretic effect of FT-A was poorly understood.

In the present study, yeast induced pyrexia mice model was used to investigate the antipyretic effect of FT-A. Given the predominant function in thermoregulation of TRPs, particularly, we focused on whether FT-A has any influences on the TRPs and their downstream cell signaling in hypothalamus and dorsal root ganglion (DRG)of yeast-induced pyrexia mice. In addition, TRPV1-transfected HEK293T cells were used to investigate the effect of FT-A on capsaicin (CAP) induced calcium influx, IL-8 and PGE~2~ production.

Material and Methods
====================

Ethics statement
----------------

The study was approved by the Research Ethics Committee of Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China. All animals were treated in according with the guidelines and regulations for the use and care of animals of the Center for Laboratory Animal Care, China Academy of Chinese Medical Sciences.

Chemicals and antibodies
------------------------

Forsythoside A (purity \> 99%) was purchased from the Chinese National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China), which structural formula was shown in Figure [1](#F1){ref-type="fig"}. Antibodies used in the study included the following: Antibodies against TRPV1, TRPA1 and TRPM8 were obtained from Alomone labs (Alomone labs, Israel), Antibodies against p-extracellular signal-regulated kinase (ERK), p-Jun N-terminal kinase (JNK), p-P38 and GAPDH were supplied from Cell Signaling Technology (Beverly, MA, USA). The enhanced chemiluminescence (ECL) kit was from Bio-Rad; EDTA-free protease inhibitor was from Roche. Lipofectamine 2000 and Fluo 4-AM were acquired from Invitrogen (Carlsbad, CA, USA). Enzyme-linked immunosorbent assay (ELISA) kits for IL-8 and PGE~2~ were purchased from R&D Systems (Minneapolis, MN, USA). Other chemical agents were purchased from Sigma-Aldrich (St Louis, MO, USA).

Yeast induced pyrexia mice model
--------------------------------

Mice were housed in groups of four per cage, and maintained in a room with controlled temperature (24±1℃), and maintained on a 12 h light/dark cycle and given ad libitum access to food and water. Pyrexia was induced in mice as described previous [@B16]. Briefly, Pyrexia was induced by injecting 20mg/kg of Brewer\'s yeast suspension or vehicle (pyrogen-free 0.9% NaCl) subcutaneously in the back behind of the neck. The rectal temperature (T~R~) was recorded by an electronic thermometer into the rectum. The rise in T~R~ was recorded after 17 h. The induction of pyrexia was confirmed by a rise in temperature of more than 1℃ and animals showing a rise in temperature less than 0.5℃ were excluded from the experiment.

Forty pyretic animals were intraperitoneal injected with FT-A at doses of 2, 4 and 8 mg/kg, and those who received Aspirin at a dose of 90 mg/kg were used as positive control. Those who administrated with saline were set as control.

Cell culture and transfection
-----------------------------

Human embryonic kidney (HEK293T) cells were purchased from the National Institute of Cells (Beijing, China), and cultured in Dulbecco\'s modified Eagle\'s medium (DMEM; Invitrogen, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, USA), penicillin(100U/ml), and streptomycin (100μg/ml). The cells were maintained at 37℃ in a humidified chamber supplemented with 5% CO~2~. Human TRPV1 expression vector (pcDNA3.0-TRPV1) was generously provided by Prof. Wan You, University of Peking. For transfection with TRPV1 plasmids, the HEK293T cells were cultured in a 6-well plate (5×10^5^ cells/well) overnight and transfected with pcDNA3.0-TRPV1 or control vector (pcDNA3.0) by lipofectamine 2000 (Invitrogen, USA) according to the manufacturer\'s instructions. These transfected cells were then subjected for further experiments.

Intracellular calcium fluorescence imaging
------------------------------------------

TRPV1-overexpressedHEK 293T cells were pretreated with FT-A for 2h. To measure calcium influx by confocal microscope, the dye Fluo-4 AM were loaded into HEK 293T-TRPV1 cells for 30min at 37℃, then Pluronic F-127 for 30 min and Hanks\' balanced salt solution (PH = 7.4) were added in the system. Cells were then challenged with 8 μMCAP in the dark. \[Ca^2+^\] in measurements were carried out using an OLYMPUS FV1000 (Tokyo, Japan) confocal microscope at room temperature. Fluo-4AM was excited at 494 nm, and the emission was recorded at 516 nm. The measured fluorescence was subtracted from the background and auto fluorescence. The fluorescent intensity was used to represent the changes in intracellular Ca^2+^ levels. The experiments were carried out 3 times in triplicate measurements.

Flow cytometry
--------------

TRPV1-overexpressedHEK 293T cells were pretreated with a serial of concentration of FT-A (0.1, 1.0, 10 μg/mL) for 2h. Cells were digested and collected by centrifugation and loaded with Fluo-4/AM and incubated for 35 min at room temperature in normal physiological buffer (NPB) containing 1.0 mM CaCl2 and0.1% (wt/vol) BSA. The cells were washed twice and resuspended in NPB containing 1.0 mM CaCl~2~. Cells were then challenged with 8 μMCAP in the dark. Fluorescence intensity was determined by flow cytometry using CELL Quest software with excitation at 488 nm and emission at 530 nm. The experiments were carried out 3 times in triplicate measurements.

Enzyme-linked immunosorbent assay
---------------------------------

Immediately after the last temperature measurements, blood was obtained from orbit, and then separated by centrifugation to obtain serum. The serum was aliquot and stored at -80℃.HEK 293T-TRPV1 cells were pretreated with FT-A for 2h followed by stimulation with CAP (8μM) for 24h. Cell culture supernatants were collected. The levels of PGE~2~ and IL-8 in the cell culture supernatants and serum of mice were detected by ELISA Kit (R&D Systems, Minneapolis, USA) according to the manufacturer\'s instructions. The absorbance was read at the wavelength of 450 nm with a microplate reader (Lab systems Dragon, Helsinki, Finland). The experiments were carried out 3 times in triplicate measurements.

Immunohistochemical analysis
----------------------------

Paraffin sections (4 μm) of tissue from the hypothalamus and DRG were mounted on slides. The sections were dewaxed by routine method and incubated with 3% H~2~O~2~for 10 min, and blocked by corresponded serum for 1 h at room temperature. Then the sections were incubated with different primary antibodies: p-ERK (1:100, Cell Signaling Technology, USA), p-JNK (1:100, Cell Signaling Technology, USA) and p-P38(1:100, Cell Signaling Technology, USA) at 4℃ overnight, respectively. For the control staining, PBS was used instead of the primary antibody. Then incubated with second antibody and stained with 3, 3-diaminobenzidine (DAB). In this procedure, rinsing with PBS was carried out between any two steps. Image-Pro Plus 6.0 System (IPP) image analysis system was used for quantitative analysis. Five fields of view were randomly selected from each slice, and an index of positive staining was determined from the area of positive staining and the optical density. The positive index was calculated as positive area integral optical density (IOD).

Western blotting analysis
-------------------------

Immediately after the last temperature measurements, the mice were sacrificed by rapid decapitation. The hypothalamus and the DRG were rapidly removed, frozen in liquid nitrogen and placed in -80℃. Total protein of hypothalamus and the DRG were extracted following the instructions of the Bradford Kit. For in vitro experiments, HEK 293T-TRPV1 cells were pretreated with FT-A for 2h followed by stimulation with CAP (8μM) for 15 min. Cells was collected and total proteins were extracted. For immunoblot analysis, equivalent amounts of protein were separated in 8% SDS-PAGE and transferred to polyvinylidene fluoride membrane (Millipore, Massachusetts, USA), which was blocked by 5% nonfat dry milk. The membrane was then incubated with appropriately diluted primary antibodies overnight at 4℃, followed by horseradish peroxidase-conjugated secondary antibodies for 1h at room temperature (RT). The immune reactive bands were detected by ECL (Bio-Rad) and visualized with the Fusion-Capt Advance (VILBER, France). The intensity of the blots was quantified by MultiGauge software according to the manufacturer\'s instruction.

Statistical Analysis
--------------------

Each experiment was repeated at least three times. Data were represented in the form of means ± SD. All the data were analyzed using the SPSS statistical package (version 13.0, USA). The data were analyzed by One-way ANOVA followed by Dunnett\'s t-test to assess the statistical significance of the differences between the study groups. Differences were considered statistically significant when *P* was less than 0.05.

Results
=======

FT-A significantly prevents yeast-induced pyrexia and inhibits production of pyrogenic factors
----------------------------------------------------------------------------------------------

We first investigate the effects of FT-A on body temperature using yeast-induced pyrexia mice model. As shown in Figure [2](#F2){ref-type="fig"}A, subcutaneous (s.c.) injection of yeast evoked a significant elevation of rectal temperature (T~R~)16h later, and reached the peak within 18h (39.28±0.41℃ versus 36.78±0.36℃ for vehicle, *P*\<0.01), then declined gradually during time period observed. However, the elevation of T~R~was significantly suppressed by FT-A at the doses of 2, 4 and 8mg/kg from the onset of the pyrexia for up to 6h after treatment with the dose-dependent manner. Especially FT-A at 8mg/kg exerted almost equivalent ability with aspirin (90 mg/kg). The overall changes of T~R~ with time was also evaluated as area under the curve (AUC) and presented with column diagram. The results showed that yeast could cause significant increase of AUC, while FT-A could markedly decrease the AUC with the dose-dependent tendency (Figure [2](#F2){ref-type="fig"}B).

Pro-inflammatory mediators and cytokines play the critical intermediary role in the process of fever, of which PGE~2~ and IL-8 are of great importance. Data of the present experiments showed that mice challenged with yeast dramatically enhanced the productions of PGE~2~ and IL-8. FT-A (4, 8mg/kg) treatment produced a marked decrease in the levels of PGE~2~ and IL-8, but a relatively weaker reduction in the FT-A (2mg/kg, Figure [2](#F2){ref-type="fig"} C and D). These findings demonstrated that FT-A exert antipyretic effect on yeast-induced fever by inhibiting the production of pyrogenic cytokines.

FT-A markedly inhibits TRPV1 expression in the hypothalamus and DRG of yeast-induced hyperthermia mice
------------------------------------------------------------------------------------------------------

Since TRPs play an important role in the thermoregulation, next we investigated whether the anti-pyretic effects of FT-A related to TRPs. The hypothalamus has long been known as a major thermo-regulatory region of the CNS, and DRG neurons involved in almost all the thermal afferent pathways, so we detected the expression of TRPs subtypes in the two tissues of yeast-induced hyperthermia mice. As shown in Figure [3](#F3){ref-type="fig"}A, the expression of TRPV1 in hypothalamus was significantly up-regulated compared with saline injected control mice. Treatment of FT-A (2, 4, 8 mg/kg) significantly decreased the expression of TRPV1 in a dose-dependent fashion, with the most apparent decrease about 80% compared to the yeast injection mice. In contrast, the expressions of TRPA1 and TRPM8 in hypothalamus of yeast injection mice were markedly downregulated compared with saline injected control mice. FT-A (4 and 8 mg/kg) increased TRPA1 protein expression (*P*\<0.05 or *P*\<0.01). However, FT-A (4 and 8 mg/kg) showed no obvious influence on TRPM8 expression, while FT-A at 2mg/kg slightly inhibited TRPM8 expression.

Consistent with these findings, we also observed significantly increased TRPV1 expression in the DRG from yeast-induced hyperthermia mice (Figure [3](#F3){ref-type="fig"}B). FT-A at the concentration of 2 mg/kg showed no obvious effect on expression of TRPV1, while 4 and 8 mg/kg of FT-A significantly inhibited the TRPV1 expression near the saline control level. The expressions of TRPA1 and TRPM8 in DRG were significantly decreased by yeast compared with saline injected control mice, while only 8 mg/kg of FT-A moderately increased the two-protein expression. Thus it can be seen that FT-A impacted TRPV1 expression most apparently.

We therefore examined whether the expression levels of TRPV1, TRPA1 and TRPM8 can be correlated with the body temperature in yeast-induced fever. We identified a strong positive correlation between the expression of TRPV1 and body temperature. In contrast, the expressions of TRPA1 and TRPM8 showed moderately negative correlation with body temperature (Figure [3](#F3){ref-type="fig"}C). Together, these results demonstrate a pivotal role of TRPV1 in yeast-induced hyperthermia as well as in the antipyretic effect of FT-A.

FT-A inhibitsIL-8 and PGE~2~ secretions and calcium influx inTRPV1 expressing cells
-----------------------------------------------------------------------------------

To test the effect of FT-A on the TRPV1 activation, we transiently transfected HEK 293T cells with TRPV1 constructs. As expected, a considerable amount of TRPV1 was detected in HEK 293T-TRPV1 cells by western blot (Figure [4](#F4){ref-type="fig"}A). In this study, we also determined the levels of IL-8 and PGE~2~ in the culture supernatants by ELISA.As shown in Figure [4](#F4){ref-type="fig"}B and C, the levels of PGE~2~ and IL-8 released from HEK 293T cells were significantly increased after stimulated with 8 μM CAP, the specific TRPV1 agonist (*P*\< 0.05). When pretreatment with various concentrations of FT-A, the production of PGE~2~and IL-8 induced by CAP were reduced in a dose-dependent manner. These data suggested that the inhibitory role of FT-Aon the releases of IL-8 and PGE~2~ inducted by CAP was mediated by TRPV1.

Stimulation of TRPV1 by CAP increases Ca^2+^ influx in heterologous systems [@B17], [@B18], in the present experiment, the intracellular Ca^2+^ influx response to CAP were monitored in TRPV1-overexpressed HEK 293T cells loaded with Fluo-4 AM by confocal microscope. As showed in Figure [5](#F5){ref-type="fig"}A and B, CAP significantly increased the intracellular level of Ca^2+^ in TRPV1-overexpressed HEK293T cells, pretreatment with FT-A (0.1, 1, 10 μg/mL) markedly abrogated the CAP-induced increase in intracellular Ca^2+^ level with a dose-dependent fashion.

To corroborate the finding that FT-A suppressed TRPV1 function, flow cytometry was performed to detect the intracellular Ca^2+^ level. Consistent with the confocal results, CAP induced Ca^2+^ influx in HEK 293T-TRPV1 cells up to 212.6% of the control. However, FT-A (0.1, 1, 10 μg/mL) significantly decreased CAP induced Ca^2+^ influx in HEK 293T-TRPV1 cells by 18.32% (*P*\<0.05), 26.93% (*P*\<0.01) and 39.15% (*P*\<0.01), respectively (Figure [5](#F5){ref-type="fig"} C and D). These results suggested that FT-A treatment inhibited the function of TRPV1 by suppressing TRPV1 sensitivity.

FT-A suppresses the MAPKs pathway activation in the yeast-induced hyperthermia mice and TRPV1 expressing cells
--------------------------------------------------------------------------------------------------------------

Previous studies indicate that a global activation of MAPK signaling occurs during the process of hyperthermia [@B19], [@B20]. To further investigate the role of FT-A in pyrexia, we examined if FT-A was able to inhibit certain signaling pathways associated with pyrexia. In this experiments, HEK 293T-TRPV1 cells were treated with FT-A, then stimulated with CAP, followed by analyzing the activation of the MAPK signaling pathway. As shown in Figure [6](#F6){ref-type="fig"}, CAP (8 μM) exposure resulted in an increase of the phosphorylated form of ERK and p38 MAPK, but not JNK/SAPK MAPK branch. Interestingly, when we treated the cells with various doses of FT-A for 2 h before stimulation with CAP and found that the activations of these signaling pathways were markedly inhibited in a dose dependent manner. Especially at the concentration of 1 and 10 μg/mL of FT-A induced a sharp decrease in their activity of ERK and p38.

To further investigate the role of FT-A on TRPV1, we detected the activation of MAPK signaling pathway on the hypothalamus and DRG of the yeast-induced fever mice. Immunohistochemical staining results showed that there was slight positive staining of the phosphorylated form of ERK, JNK and p38MAPK in the hypothalamus of the normal mice, while the signals significantly increased in the yeast-treated mice. However, the positive signals were remarkably reduced in the FT-A groups compared with that of the yeast group. Quantification of results showed that, compared to yeast group, there were obvious statistical significance in the FT-A-treated group (Figure [7](#F7){ref-type="fig"} A and B, Figure [8](#F8){ref-type="fig"} A and B). Downregulation of phosphorylation of all the three subtypes of MAPK was confirmed using Western blot in the hypothalamus and DRG of the yeast-induced fever mice (Figure [7](#F7){ref-type="fig"} C and Figure [8](#F8){ref-type="fig"}C). As to the difference of FT-A on JNK phosphorylation between HEK 293T-TRPV1 cells and the yeast-induced fever mice, we think that the HEK 293T-TRPV1 cells could not fully mimic the *in vivo* biological process, which is the universal limitation of the *in vitro* cell model. Taken together, the results demonstrate that FT-A suppressed MAPK activation in mediating downstream responses to TRPV1 activation.

Discussion
==========

Fructus Forsythiae has been widely used in the treatment of various inflammatory febrile diseases in Chinese medical practice. Because of the beneficial clinical impact, it is necessary to understand how its active components exerts therapeutic function. FT-A, a phenylethanoid glycoside, the main and most abundant active ingredient in Fructus Forsythiae, has been known to possess antimicrobial and antiviral activities. However, its potential role in the antipyretic and its underlying pharmacological mechanism remain unclear. Results of the present study demonstrated that FT-A alleviated fever of yeast induced pyrexia mice via suppression TRPV1 expression and activation, inhibition MAPKs activation of the hypothalamus and DRG, and subsequently decreased secretion of pyretic cytokine as PGE~2~ and IL-8. Additionally, studies using the gene-manipulated strategy in TRP channel-deficient HEK293T cells further support the observation that FT-A suppressed TRPV1 activation through inhibiting MAPK pathway. The above findings were summarized in Figure [9](#F9){ref-type="fig"}. These findings provide the mechanistic explanation, at least in part for the antipyretic effect of FT-A against fever related disease, such as inflammatory fever.

Yeast induced pyrexia is called pathogenic fever by increasing the synthesis of prostaglandin, and is considered as a useful model for the screening of plants materials as well as synthetic drugs for their antipyretic effect [@B21], [@B22]. Several cytokines such as IL-8 and IL-1 are characterized as endogenous pyrogens, and the inhibition of these pyrogensis responsible for the antipyretic effect [@B21]. In the present study, intraperitoneal administration of FT-A significantly attenuated rectal temperature of yeast induced febrile mice. Therefore, it can be postulated that FT-A maybe interfere with the release of prostaglandin and pyrogenic cytokines. So, we tested the effect of FT-A on PGE~2~ and IL-8 secretion by yeast induced pyretic animals. The data showed that FT-A reduced the PGE~2~ and IL-8 levels in febrile mice.

The molecular components and mechanisms involved in pyrexia formation are now starting to be unfolded. The identification and cloning of the TRPs, such as TRPV1, TRPM8 and TRPA1, represented a significant step in the clarification of the molecular mechanisms underlying thermoregulation of the body. Thermo sensitive TRPs were shown to be highly expressed in nociceptive pathways, specialized somato sensory neurons in the trigeminal and DRG that project axonal processes to the outer layers of the skin [@B23]-[@B25]. By contrast, expression levels for TRP channels in the brain are much lower than that in the DRG [@B26]. Notably, the channel activity of TRPV1 is remarkably up-regulated by inflammatory mediators [@B23]. Since TRPs receptor has emerged as a key therapeutic target for inflammatory fever management because of their central implication in thermoregulation, we observed whether the antipyretic effect of FT-A related to TRPs. Our present results revealed that FT-A could markedly inhibited protein expressions of TRPV1, and slightly increased the expressions of TRPA1 and TRPM8in the hypothalamus and DRG. Furthermore, we identified a strong positive correlation between the expression level of TRPV1 and the body temperature, while the expression levels of TRPA1 and TRPM8 were not obviously corrected with the body temperature, which implied that TRPV1 may contribute most to the anti-pyretic effect of FT-A.

Potentiating of TRPV1 channel activity, along with an incremented TRPV1 surface expression are major events underlying the nociceptors activation and sensitization that leads to thermal regulation [@B27]. At the molecular level, TRPV1 belongs to the TRP family of cation channels, and is a Ca^2+^-permeable, ionotropic receptor non-selective channel. Upon TRPV1activation by thermal stimuli or noxious chemical, leads to change of internal Ca^2+^, which itself represents a powerful influence on cellular signaling, feeding back upon TRPV1 function [@B28]. Increasing Ca^2+^ influx contributes to several pathological conditions, including pro-inflammatory cytokines secretion. In the present study, we constructed HEK 293T-TRPV1 cells, which stably overexpressed TRPV1, to explore the roles of TRPV1 on the anti-pyrexia effects of FT-A. Our results also showed that activation of TRPV1 by CAP resulted in marked increase of internal Ca^2+^, in turn, triggered the release of pro-inflammatory agents as IL-8 and PGE~2~, which were inhibited by FT-A in a concentration dependent manner. These results suggest that FT-A treatment inhibits the function of TRPV1 either by a decrease in the expression of TRPV1 or an inhibition in TRPV1 sensitivity.

Identified signal transduction events mediating the TRPV1 activation include transient intracellular Ca^2+^ rises and phosphorylation of kinases belonging to the p38, ERK and JNK mitogen activated protein kinase (MAPK) cascades suggesting that all three MAPK pathways may be involved in downstream TRPV1 effects [@B29]. In the present study, we found that the activation of three subfamilies of MAPKs, including ERK, JNK, and p38 MAPKs in the DRG and hypothalamus of the pyrexia mice induced by yeast. However, the increased the activation of MAPKs was downregulated when administrated with FT-A, which indicated that ERK, JNK, and p38 MAPKs were involved in the antipyretic effect of FT-A. In support of this finding, immune reactivity assays demonstrated increased phosphorylation of MAPKs in hypothalamus and DRG of pyretic mice, while decreased in mice receiving FT-A treatment.

In summary, we have demonstrated that FT-A alleviates pyrexia through inhibiting the secretion of inflammatory mediators PGE~2~ and IL-8, which may be associated with the suppression of the TRPV1 expression, decease of calcium influx, and inhibition of phosphorylation of MAPKs. Our findings provide new insights into the molecular mechanism underlying the effect of FT-A on pyrexia and suggest that FT-A may serve as a potent drug candidate for inflammatory fever, and that the therapeutic action of Fructus Forsythiae on pyretic related disease is, in part, due to the FT-A activities.

The investigation was supported by grants from the projects of China Academy of Chinese Medical Sciences (Z02096).

Author contributions
====================

N Lin and XY Kong conceived and designed the experiments; CL Liu, HC Su, and HY Wan performed the experiments; X Wu and QX Qin analyzed the data; XY Kong wrote the manuscript and N Lin reviewed it.

![The chemical structure of Forsythoside A.](ijbsv13p0065g001){#F1}

![FT-A attenuates yeast-induced increase of rectal temperature and pyrogenic cytokines in the plasma. (A)Intraperitoneal injection of FT-A significantly antagonized yeast-induced pyrexia on mice. (B) Changes of rectal temperature expressed by area under the curve after yeast-induced pyrexia (t=17 to 22). (C) PGE~2~ and IL-8 levels in the serum were also detected by enzyme-linked Immunosorbent assay (ELISA). All bar graphs represent mean ± SD of 3 independent experiments. ^\#\#^*P*\< 0.01,^\#\#\#^*P*\< 0.001, significantly different from the Normal group; \**P*\<0.05, \*\**P*\< 0.01, \*\*\**P*\< 0.001, significantly different from the Yeast group.](ijbsv13p0065g002){#F2}

![FT-Ainhibits TRPV1 expression while increases TRPA1 and TRPM8 expression in the hypothalamus and DRG of the mice with yeast-induced pyrexia. Expressions ofTRPV1, TRPA1 and TRPM8 were evaluated in the hypothalamus (A) and DRG (B) by Western blotting. Values are Mean ± SD of 5 mice per group.^\#^*P*\<0.05, ^\#\#^*P*\< 0.01,^\#\#\#^*P*\< 0.001 significantly different from the Normal group, \**P*\<0.05, \*\**P*\< 0.01, \*\*\**P*\< 0.001 significantly different from the Yeast group.(C)Correlations between the expression of TRPs and the change of rectal temperature were assessed in the mice with yeast-induced pyrexia (n=5 samples per group).](ijbsv13p0065g003){#F3}

![FT-A inhibits PGE~2~ and IL-8 productions through TRPV1 signal. (A) Expression of TRPV1 protein in HEK 293T cells, HEK 293T mock cells and HEK 293T-TRPV1 cells by Western blot utilizing human anti-TRPV1 polyclonal antibody. HEK 293T-TRPV1 cells were incubated with 0.1, 1 and 10 μg/mL FT-A for 2 h, and then further treated with 10 μM CAP for24 h. The levels of PGE~2~ (B) and IL-8 (C) in cell supernatants were detected by ELISA. Results were shown as mean ± SD values of three independent experiments. ^\#\#^*P*\< 0.01, significantly different from the Control group; \**P*\<0.05, \*\**P*\< 0.01, significantly different from the CAP group.](ijbsv13p0065g004){#F4}

![FT-A suppresses capsaicin-induced Ca^2+^ influx in HEK 293T-TRPV1 cells. (A). HEK 293T-TRPV1 cells were pre-incubated with 10 μM Fluo-4/AM fluorescence for 15 min at 37℃, and then treated with 0.1, 1 and 10 μg/Ml FT-A for 2 h, with or without 10 μM CAP for 15 min. Ca^2+^ influx was determined by Confocal microscopic analysis (A) and flow cytometry (C). Quantitative analysis of the mean Ca^2+^concentration for confocal microscopic analysis (B) and flow cytometry (D). Values are Mean ± SD from 3 independent experiments. ^\#\#\#^*P*\< 0.001significantly different from the Control group; \**P*\<0.05, \*\**P*\< 0.01 significantly different from the CAP group.](ijbsv13p0065g005){#F5}

![FT-A suppresses MAPKs activation in the HEK 293T-TRPV1 cells induced by CAP. (A) HEK 293T-TRPV1 cells were pre-incubated with or without of FT-A for 2 h, following treatment with 10 μM CAP for 15 min. Total protein was extracted and subjected to Western blot analysis. And relative amounts of each protein were determined by densitometric analysis. One of three experiments with similar results is shown. Data are represented as the mean ± SD. ^\#\#\#^*P*\< 0.001significantly different from the Control group; \*\**P*\<0.01, \*\*\**P*\< 0.001 significantly different from the CAP group.](ijbsv13p0065g006){#F6}

![FT-A inhibits MAPKs activation in the hypothalamus on mice with yeast-induced pyrexia. The pyretic mice were intraperitoneal injected with FT-A at doses of 2, 4 and 8 mg/kg, and the expression of p-ERK, p-JNK and p-P38 in the hypothalamus were detected by immunohistochemical staining (A) and Western blotting(C). Quantitative analysis of the mean amount of each protein was determined by integral optical density. One of three experiments with similar results is shown. Data are represented as the mean ± SD. ^\#\#\#^*P*\< 0.001, significantly different from the Normal group; \**P*\<0.05, \*\**P*\< 0.01, \*\*\**P*\< 0.001, significantly different from the Yeast group.](ijbsv13p0065g007){#F7}

![FT-A inhibits MAPKs activation in the DRG on mice with yeast-induced pyrexia. The pyretic mice were intraperitoneal injected with FT-A at doses of 2, 4 and 8 mg/kg, and the expressions of p-ERK, p-JNK and p-P38 in the DRG were detected by immunohistochemical staining (A) and Western blotting(C). Quantitative analysis of the mean amount of each protein was determined by integral optical density. One of three experiments with similar results is shown. Data are represented as the mean ± SD.^\#\#^*P*\< 0.01^\#\#\#^*P*\< 0.001, significantly different from the Normal group; \**P*\<0.05, \*\**P*\< 0.01, \*\*\**P*\< 0.001, significantly different from the Yeast group.](ijbsv13p0065g008){#F8}

![Model depicting the proposed mechanism by which FT-A exert antipyretic effect. Target-derived pyrogenic cytokines such as PGE~2~ and IL-8, stimulated TRPV1 activation, inducing Ca^2+^influx, subsequently activated MAPKs signal pathway. At the nucleus, MAPKs signaling can increase TRPV1 expression and pyrogenic cytokines. Consequently, the increased TRPV1 could be transported to the membrane of the cell, and the elevated PGE~2~ and IL-8 could be secreted out of the cell, and activated TRPV1. Red arrow mark indicates that an inhibition or a downregulation in this study observed.](ijbsv13p0065g009){#F9}
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